Company Description
Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity.
The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans.
It also develops Rejuva, a novel adeno-associated virus delivered pancreatic gene therapy platform that is designed to enable long-term remission of T2D and obesity by durably altering metabolic hormone function in the pancreatic islet cells of patients.
Fractyl Health, Inc. was formerly known as Fractyl Laboratories Inc. and changed its name to Fractyl Health, Inc. on June 09, 2021.
The company was incorporated in 2010 and is headquartered in Burlington, Massachusetts.
| Country | United States |
| Founded | 2010 |
| IPO Date | Feb 2, 2024 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 94 |
| CEO | Dr. Harith Rajagopalan M.D., Ph.D. |
Contact Details
Address: 3 Van De Graaff Drive, Suite 200 Burlington, Massachusetts 01803 United States | |
| Phone | 781-902-8800 |
| Website | fractyl.com |
Stock Details
| Ticker Symbol | GUTS |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $15.00 |
| CIK Code | 0001572616 |
| Employer ID | 27-3553477 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Dr. Harith Rajagopalan M.D., Ph.D. | Co-Founder, Chief Executive Officer and Director |
| Jay D. Caplan BSEE, MBA | Co-Founder, Chief Product Officer and President |
| Dr. Timothy J. Kieffer Ph.D. | Chief Scientific Officer |
| Lisa A. Davidson MBA | Chief Financial Officer and Treasurer |
| Sarah S. Toomey Esq. | General Counsel and Corporate Secretary |
| Dr. Helmut Giersiefen | Head of Business Development |
| Adrian Kimber | Chief Commercial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 1, 2024 | 10-K | Annual Report |
| Apr 1, 2024 | 8-K | Current Report |
| Apr 1, 2024 | 8-K | Current Report |
| Feb 16, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Feb 14, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Feb 6, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Feb 6, 2024 | 8-K | Current Report |
| Feb 2, 2024 | 424B4 | Prospectus |
| Feb 1, 2024 | EFFECT | Notice of Effectiveness |
| Feb 1, 2024 | CERT | Certification by an exchange approving securities for listing |